CenterBook Partners LP Grows Stake in Roivant Sciences Ltd. $ROIV
CenterBook Partners LP significantly increased its stake in Roivant Sciences Ltd. by 147.5% in Q3, now holding 247,443 shares valued at $3.74 million. Despite institutional growth, company insiders have been net sellers, disposing of over 10 million shares recently. Wall Street analysts maintain a largely positive outlook, with several firms raising their price targets for ROIV.
Eric Venker Sells 200,000 Shares of Roivant Sciences (NASDAQ:ROIV) Stock
Eric Venker, CEO of Roivant Sciences (NASDAQ:ROIV), sold 200,000 shares of the company's stock on February 13th at an average price of $26.49, totaling $5.30 million. This sale reduced his position by 10.78% and is part of a pattern of sales since December, amounting to approximately 875,000 shares for $20.0 million. Roivant Sciences is currently trading near its 52-week high and holds a consensus "Moderate Buy" rating from analysts.
Why (ROIV) Price Action Is Critical for Tactical Trading
This article analyzes Roivant Sciences Ltd. (NASDAQ: ROIV) stock, highlighting strong sentiment across all horizons supporting an overweight bias despite elevated downside risk. It details three AI-generated institutional trading strategies—Position, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop loss zones for different risk profiles. The piece also provides a multi-timeframe signal analysis, showing support and resistance levels for near-term, mid-term, and long-term horizons, emphasizing the use of AI for real-time trading signals and risk management.
Roivant Sciences Advances PHocus Trial Milestone As Shares Trade Below Targets
Roivant Sciences' subsidiary Pulmovant has completed patient enrollment for its Phase 2 PHocus trial of mosliciguat for pulmonary hypertension, ahead of schedule. This clinical milestone comes as Roivant's shares have shown significant recent momentum, despite trading below analyst targets and the company reporting a net loss. Investors are advised to monitor upcoming data readouts and analyst target shifts, while also being aware of minor risks like recent insider selling.
Roivant Sciences Advances PHocus Trial Milestone As Shares Trade Below Targets
Roivant Sciences (NasdaqGS:ROIV) has achieved a significant clinical milestone with the early completion of patient enrollment in the Phase 2 PHocus trial for mosliciguat, targeting pulmonary hypertension. This progress comes as the company's shares trade approximately 20% below analyst targets despite strong recent momentum. Investors are advised to watch for upcoming data readouts and consider both the clinical advancement and the existing financial risks, including ongoing net losses and insider selling.
Citi Raises Roivant Sciences (ROIV) PT to $35 Following Positive Phase 2 Brepocitinib Data
Citi raised its price target for Roivant Sciences (ROIV) to $35 from $26, maintaining a Buy rating, following positive Phase 2 data for brepocitinib in cutaneous sarcoidosis. H.C. Wainwright also increased its price target to $33, while Bank of America adjusted its target to $26 with a Neutral rating, all influenced by the promising results for the drug. These revisions reflect increased sales forecasts and growth potential for brepocitinib.
Roivant Sciences Advances PH Programs As Investors Weigh Pipeline Milestones
Roivant Sciences (NasdaqGS:ROIV) has reported significant clinical progress, including the completion of patient enrollment for the Phase 2 PHocus trial and positive Phase 2 data for brepocitinib in cutaneous sarcoidosis. These advancements highlight the company's focus on developing therapies for rare conditions and attract investor attention to its pipeline milestones. While the company remains loss-making, the clinical updates are crucial for assessing its long-term potential in specialty and rare disease drug development.
Citi raises Roivant Sciences (ROIV) PT to $35 following positive phase 2 brepocitinib data
Citi raised its price target for Roivant Sciences (ROIV) to $35, up from $20, while maintaining a Buy rating. This adjustment follows positive Phase 2 data for brepocitinib in patients with non-anterior uveitis. The trial's success, particularly against a high placebo response, suggests strong therapeutic potential and differentiation for the drug.
Citi Raises Roivant Sciences (ROIV) PT to $35 Following Positive Phase 2 Brepocitinib Data
Citi has raised its price target for Roivant Sciences (ROIV) to $35 from $26, maintaining a Buy rating, after positive Phase 2 data for their drug brepocitinib in treating cutaneous sarcoidosis. H.C. Wainwright also increased its price target to $33, citing impressive Phase 2 results. Bank of America similarly raised its price target to $26 following inline Q3 2026 results and the same positive brepocitinib data, reflecting increased sales forecasts.
Insider Selling: Roivant Sciences (NASDAQ:ROIV) Director Sells 375,784 Shares of Stock
Roivant Sciences (NASDAQ:ROIV) Director Daniel Allen Gold sold 375,784 shares of the company's stock for approximately $9.96 million on February 13, adding to a series of significant insider sales in recent months. Despite overall positive analyst ratings and increased institutional holdings, these large insider disposals, along with a Weiss downgrade and reduced FY2027 EPS forecasts, are creating mixed sentiment and potential selling pressure for the stock. Roivant shares are currently trading around $26.45, with a market capitalization of $18.4 billion.
Roivant Sciences (NASDAQ:ROIV) Director Daniel Allen Gold Sells 425,000 Shares
Roivant Sciences Director Daniel Allen Gold recently sold 425,000 shares of ROIV stock for over $11 million, along with several other large dispositions in recent months. Despite these insider sales, Wall Street sentiment remains largely positive, with an average price target of $28.69 and institutional ownership at nearly 64.8%. The company, a biopharmaceutical firm focused on developing innovative therapies, saw its shares trading down 1.1% at $26.45, with a market cap of $18.4 billion.
Citi Raises Roivant Sciences (ROIV) PT to $35 Following Positive Phase 2 Brepocitinib Data
Citi raised its price target for Roivant Sciences (ROIV) to $35 from $26, maintaining a Buy rating, after positive Phase 2 data for brepocitinib in cutaneous sarcoidosis. H.C. Wainwright also increased its price target to $33, while Bank of America set a $26 target with a Neutral rating, also citing the promising brepocitinib results and increased sales forecasts. Roivant Sciences is a clinical-stage biopharmaceutical company developing new medicines.
Citi Raises Roivant Sciences (ROIV) PT to $35 Following Positive Phase 2 Brepocitinib Data
Citi raised its price target for Roivant Sciences (ROIV) to $35 from $26, maintaining a Buy rating, after positive Phase 2 data for brepocitinib in cutaneous sarcoidosis. H.C. Wainwright also increased its price target to $33, and Bank of America raised its target to $26, all citing the impressive brepocitinib data and its growth potential. Roivant Sciences is a clinical-stage biopharmaceutical company, and these target increases reflect an increased sales forecast for the drug.
HC Wainwright Analysts Increase Earnings Estimates for ROIV
HC Wainwright analysts have increased their FY2026 EPS estimates for Roivant Sciences (NASDAQ:ROIV) to ($1.55) from ($1.61) and maintained a "Buy" rating with a $33 price target. Other firms like Citigroup, Goldman Sachs, and Leerink also have bullish outlooks, contributing to an average analyst rating of “Moderate Buy” and a $28.69 price target for the stock. Despite these positive analyst views, company insiders have recently sold a significant number of shares, totaling approximately $244.5 million in the last quarter.
Roivant Sciences (NASDAQ:ROIV) Insider Sells $8,985,003.27 in Stock
Roivant Sciences (NASDAQ:ROIV) insider Mayukh Sukhatme sold 339,441 shares totaling nearly $9 million on February 9th, adding to previous sales in December 2025. Despite these sales, Sukhatme still holds substantial direct ownership in the company. The stock is currently rated a "Moderate Buy" by analysts, with a target price of $28.69.
Citi Maintains Roivant Sciences(ROIV.US) With Buy Rating, Maintains Target Price $35
Citi analyst Samantha Semenkow has reiterated a Buy rating for Roivant Sciences (ROIV.US) and maintained a target price of $35. According to TipRanks data, the analyst has a 45.7% success rate and a 0.9% average return over the past year. This report is for informational purposes only and does not constitute investment advice.
Impax Asset Management Group plc Sells 200,000 Shares of Roivant Sciences Ltd. $ROIV
Impax Asset Management Group plc reduced its stake in Roivant Sciences Ltd. by selling 200,000 shares, bringing its total ownership to 1,800,000 shares valued at $27.23 million. Other institutional investors also adjusted their positions, with Goldman Sachs and UBS AM increasing their holdings, while several insiders sold significant amounts of company stock. Analyst ratings recommend Roivant Sciences as a "Moderate Buy" with a consensus price target of $28.69.
TD Cowen Remains Bullish on Roivant Sciences Ltd. (ROIV) – Here’s Why
TD Cowen has reiterated a bullish stance on Roivant Sciences Ltd. (ROIV), increasing its price target to $38 from $28 while maintaining a Buy rating. This update followed positive Phase 2 results for brepocitinib in cutaneous sarcoidosis (CS) and the company's Q3 2025 financial report. Roivant also announced an NDA submission for brepocitinib in dermatomyositis and confirmed a strong cash position supporting its runway into profitability.
Candriam S.C.A. Increases Position in Roivant Sciences Ltd. $ROIV
Candriam S.C.A. significantly increased its stake in Roivant Sciences Ltd. (NASDAQ:ROIV) by 43.5% in the 3rd quarter, now holding 2,157,995 shares valued at approximately $32.65 million. This institutional buying comes despite recent selling by corporate insiders, including CEO Eric Venker and Mayukh Sukhatme, who collectively offloaded over 12 million shares worth about $262 million in the last 90 days. Analyst sentiment remains largely positive, with a "Moderate Buy" consensus and an average target price of $27.56, while the stock recently saw a 7.2% increase.
Roivant Sciences stock price target raised to $33 from $26 at H.C. Wainwright
H.C. Wainwright raised its price target on Roivant Sciences to $33 from $26, maintaining a Buy rating after the company announced positive Phase 2 data for brepocitinib in cutaneous sarcoidosis. This drug is the first to show positive placebo-controlled trial results for this indication, which currently lacks FDA-approved therapies. The firm highlighted brepocitinib's comprehensive inhibition of inflammatory activity and its potential to target over 15,000 patients across multiple indications by 2028.
Roivant Sciences stock price target raised to $38 from $36 at Goldman Sachs
Goldman Sachs has increased its price target for Roivant Sciences (NASDAQ:ROIV) to $38 from $36, maintaining a Buy rating, citing its position at the start of a multi-year catalyst path with potential to become a mid-cap biotech growth story. The firm highlights four of five remaining clinical catalysts scheduled for 2026, which could unlock over $10 billion in unadjusted peak sales, particularly emphasizing the underappreciated potential of mosliciguat in PH-ILD. Despite analysts anticipating a sales decline this year and the company currently not being profitable, Roivant's stock has shown impressive momentum, returning 25.94% in the past week and 156.44% over the last year, and holds more cash than debt.
Citi raises Roivant Sciences stock price target to $35 from $26
Citi has increased its price target for Roivant Sciences (NASDAQ: ROIV) to $35 from $26, while reaffirming a Buy rating on the biopharmaceutical stock. This significant 35% revision comes despite the company reporting Q3 2026 earnings that missed analyst expectations, showing a larger-than-expected loss and revenue shortfall. Citi analyst Samantha Semenkow's confidence appears to stem from Roivant's strong cash position and promising drug pipeline developments.
TD Cowen Remains Bullish on Roivant Sciences Ltd. (ROIV) - Here's Why
TD Cowen has reaffirmed its bullish stance on Roivant Sciences Ltd. (ROIV), increasing its price target to $38 from $28 and maintaining a Buy rating after the company announced positive Phase 2 results for brepocitinib in cutaneous sarcoidosis and reported its Q3 2025 financial results. Roivant also submitted an NDA for brepocitinib in dermatomyositis and anticipates Phase 3 data for non-infectious uveitis in H2 2026, while holding $4.5 billion in cash and equivalents to support its cash runway into profitability. The biopharmaceutical company is actively developing transformative medicines across various therapeutic areas.
Roivant Sciences stock hits all-time high at 26.35 USD By Investing.com
Roivant Sciences (ROIV) stock reached an all-time high of $26.35, marking a 137.1% increase over the past year. This surge reflects strong investor confidence despite a recent Q3 2026 earnings report showing a larger-than-expected loss and revenue shortfall. The company's robust cash position and promising drug pipeline are believed to be driving positive investor sentiment.
Roivant Sciences stock hits all-time high at 26.35 USD
Roivant Sciences (ROIV) stock has reached an all-time high of $26.35, marking a 137.1% increase over the past year, despite recent Q3 2026 earnings reporting a larger-than-expected loss and revenue shortfall. The surge, which places the stock almost 3x above its 52-week low, reflects strong investor confidence in the company's strategic initiatives and robust cash position, despite analysts expecting a sales decline this year. Roivant's market capitalization stands at approximately $18.5 billion, and it holds more cash than debt.
Roivant Sciences Ltd. $ROIV Shares Bought by New York State Common Retirement Fund
New York State Common Retirement Fund increased its stake in Roivant Sciences Ltd. (NASDAQ:ROIV) by 25.4% to 229,037 shares, now valued at approximately $3.465 million. This comes despite significant insider selling, with directors and CFOs offloading over $262 million worth of shares recently. Roivant reported a Q3 loss and lower-than-expected revenue, yet also announced positive Phase 2 clinical trial results for brepocitinib and completed enrollment for another Phase 2 study, leading to several analyst upgrades and a "Moderate Buy" consensus rating.
Roivant Sciences stock rockets after brepocitinib Phase 2 win — what ROIV investors watch next
Roivant Sciences (ROIV) saw its stock jump over 20% after reporting positive Phase 2 data for brepocitinib in cutaneous sarcoidosis and submitting a New Drug Application for dermatomyositis. Despite growing losses, analysts are optimistic about the drug's blockbuster potential. Investors are now watching to see if the momentum holds, for potential Phase 3 advancement, and for a March 2026 jury trial regarding Moderna's lipid nanoparticle technology.
Roivant signals multiple pivotal trial readouts and accelerates brepocitinib phase III launch in 2026
This article from MSN indicates that Roivant Sciences is anticipating several pivotal trial readouts in the near future. Furthermore, the company plans to accelerate the launch of its brepocitinib phase III trial, now scheduled for 2026.
Roivant Sciences (ROIV) Q3 Loss Of US$265.9 Million Tests Bullish Profitability Narrative
Roivant Sciences (ROIV) reported a Q3 2026 loss of US$265.9 million and total revenue of US$2.0 million, falling short of bullish profitability narratives. The company's trailing 12-month net loss stands at US$809.2 million despite forecasts of 50.97% annual earnings growth. While Roivant has multiple late-stage pipeline products, its revenue remains small, and its P/B ratio of 4.3x is above the industry average, indicating valuation is driven more by future growth expectations than current profitability.
Roivant Sciences (ROIV) Q3 Loss Of US$265.9 Million Tests Bullish Profitability Narrative
Roivant Sciences (ROIV) reported a Q3 2026 loss of US$265.9 million and a basic EPS loss of US$0.38, with revenue dropping to US$2.0 million from US$9.0 million in Q3 2025. Despite forecasts for significant growth and eventual profitability, the company's current financial performance, including a trailing 12-month net loss of US$809.2 million, creates a notable gap from these bullish narratives. Investors are left to weigh the company's unchanged pipeline count against its small and shrinking revenue base, and a P/B ratio higher than the industry average despite ongoing losses.
Roivant stock surges on brepocitinib skin-disease data; what to watch into Monday
Roivant Sciences Ltd. shares surged 22.4% after reporting positive Phase 2 results for its immune-modulating drug, brepocitinib, in a rare skin disease, cutaneous sarcoidosis. The drug significantly outperformed placebo, with no serious adverse events, and a Phase 3 trial is planned for 2026. Investors are now closely watching the FDA's response to a dermatomyositis submission and upcoming fresh analyst commentary and Q4 2025 financial results.
Roivant Sciences Ltd. (NASDAQ:ROIV) Q3 2025 Earnings Call Transcript
Roivant Sciences Ltd. (NASDAQ:ROIV) held its Q3 2025 earnings call, highlighting positive Phase II results for brepocitinib in cutaneous sarcoidosis, with CEO Matthew Gline and Priovant CEO Ben Zimmer presenting. The company announced significant progress across its pipeline, including NDA submission for brepocitinib in dermatomyositis and full enrollment for Phase IIb studies of IMVT-1402 in D2T RA and moslusept in PH-ILD. Roivant reiterated a busy 2026 with pivotal readouts and the upcoming jury trial against Moderna, maintaining a strong cash position of $4.5 billion.
Roivant Sciences (ROIV) Soars 19.4% as Pipeline Drugs Progress
Roivant Sciences (ROIV) saw its share price jump by 19.4% after encouraging results from its pipeline projects, with one drug, brepocitinib, already seeking NDA approval for dermatomyositis and showing strong results in cutaneous sarcoidosis trials. Despite this progress, the company reported a net loss of $265.89 million for the third quarter. Other business units are also advancing clinical trials for various autoimmune and inflammatory diseases.
Roivant Sciences (ROIV) Soars 19.4% as Pipeline Drugs Progress
Roivant Sciences (ROIV) experienced a significant 19.4% surge in its stock price, reaching a new all-time high, driven by positive progress in its pipeline projects. The company's unit, Priovant, reported strong clinical trial results for Brepocitinib in cutaneous sarcoidosis and submitted a new drug application for brepocitinib to treat dermatomyositis. Despite these advancements, Roivant reported a net loss for the third quarter, swinging from a net income in the prior year.
Roivant Sciences Q3 2026 Earnings Call Transcript
Roivant Sciences held its Q3 2026 earnings call, announcing positive Phase 2 results for brepocitinib in cutaneous sarcoidosis (CS), with a statistically significant 21.6-point placebo-adjusted improvement in CSAMI and a 100% response rate for the 45mg dose, along with a consistent safety profile. The company also confirmed an NDA filing for brepocitinib in dermatomyositis, full enrollment for IMVT-1402's D2T-RA Phase 2b and mosliciguat's PH-ILD studies, and a busy catalyst-rich development timeline including a Phase 3 for brepocitinib in CS and the NIU Phase 3 readout in H2 2026. Despite a Q3 non-GAAP net loss of $167 million, Roivant maintains a strong cash position of approximately $4.5 billion and is preparing for a jury trial against Moderna starting March 9th.
Roivant Sciences Ltd. (ROIV) Reports Q3 Loss, Misses Revenue Estimates
Roivant Sciences Ltd. (ROIV) reported a Q3 loss of $0.24 per share, surpassing the Zacks Consensus Estimate of a $0.27 loss but missing revenue estimates with $2 million against an expected $6.12 million. Despite the revenue miss, the company's EPS beat marks a 9.43% surprise. The stock currently holds a Zacks Rank #2 (Buy), indicating potential market outperformance in the near future.
Roivant Sciences Q4 2025 slides: positive brepocitinib data drives pipeline momentum
Roivant Sciences' Q4 2025 results missed analyst expectations, but its shares surged due to positive clinical data for brepocitinib in cutaneous sarcoidosis. The company's pipeline progress, including other drug candidates and upcoming catalysts like a jury trial in March 2026, is driving investor confidence despite current financial challenges. Roivant holds a strong cash position to support its ambitious clinical development plans.
Roivant Sciences (ROIV) Is Up 19.4% After Advancing Phase 2 Pipeline Despite Wider Quarterly Loss
Roivant Sciences (ROIV) saw a 19.4% stock increase despite reporting a wider net loss of US$265.89 million in Q3 2025, with sales of US$2.00 million. The positive market reaction is attributed to significant advancements in its Phase 2 pipeline, including progress in rare inflammatory and pulmonary diseases through its subsidiaries Priovant and Pulmovant, and positive data for brepocitinib in cutaneous sarcoidosis. The company's investment narrative now heavily relies on the success of these pipeline assets, intensifying focus on execution risk and trial outcomes.
Roivant Sciences Stock Rises 17% Over Positive Data From Phase 2 Study Of Brepocitinib
Roivant Sciences Ltd. (ROIV) shares rose approximately 17% following positive results from its Phase 2 study of brepocitinib for cutaneous sarcoidosis. The study showed significant improvement in disease activity with brepocitinib compared to placebo, along with rapid, sustained improvements and a consistent safety profile. The stock is currently trading at $24.92, an increase of 17.88% from its previous close.
Roivant Sciences earnings missed by $0.07, revenue fell short of estimates
Roivant Sciences (NASDAQ: ROIV) reported fourth-quarter EPS of $-0.380, missing analyst estimates by $0.07. The company's revenue for the quarter was $1.99 million, which also fell short of the consensus estimate of $5.13 million. Despite the earnings miss, Roivant Sciences' stock price has shown a strong performance over the last 12 months, increasing by 94.120%.
Pfizer-backed Priovant scores again with fast-rising brepocitinib in midstage study
Priovant Therapeutics, backed by Pfizer, announced positive midstage results for its TYK2/JAK1 inhibitor, brepocitinib, in treating cutaneous sarcoidosis. This marks the first industry-sponsored, placebo-controlled trial to show positive results for the condition, leading Priovant to plan a phase 3 study. Analysts at Leerink Partners called the results "exceptional," with the 45-mg dose achieving a 100% response rate in multiple endpoints.
Roivant Sciences Ltd. Reports Positive Phase 2 Results and Financial Performance for Q3 2025
Roivant Sciences Ltd. has announced positive Phase 2 results for brepocitinib in cutaneous sarcoidosis (CS), showing significant improvement compared to placebo. The company's Q3 2025 financial report indicates consolidated cash of $4.5 billion, supporting a cash runway into profitability, despite increased R&D and G&A expenses. Roivant is also progressing with other pipeline initiatives, including an NDA submission for brepocitinib in dermatomyositis and Phase 3 studies, with several key data readouts anticipated in the second half of 2026.
Roivant Sciences Ltd. (ROIV) Misses Q3 EPS by 7c
Roivant Sciences Ltd. (ROIV) reported its Q3 earnings, missing analyst estimates for both EPS and revenue. The company announced a Q3 EPS of ($0.38), which was $0.07 worse than the estimated ($0.31), and revenue of $1.99 million, significantly below the consensus estimate of $5.13 million.
Roivant Sciences Ltd. SEC 10-Q Report
Roivant Sciences Ltd. (ROIV) released its Form 10-Q report for the quarter ended December 31, 2025, detailing a significant decrease in revenue and a net loss compared to the previous year. Despite financial challenges, the company highlighted progress in its pipeline, including positive Phase 2 results for brepocitinib and fully enrolled trials for IMVT-1402 and mosliciguat, with topline data expected in the second half of 2026. Roivant continues to operate with its 'Vant' subsidiary model to advance its diverse portfolio of investigational medicines.
Roivant’s brepocitinib delivers rapid, sustained remissions in cutaneous sarcoidosis — first positive placebo-controlled trial
Roivant Sciences (Nasdaq: ROIV) announced positive Phase 2 results for brepocitinib in cutaneous sarcoidosis (CS), showing significant improvement in disease activity and functional remission. The company plans to advance brepocitinib to a Phase 3 study in CS in 2026 and has submitted a New Drug Application (NDA) for brepocitinib in dermatomyositis. Roivant also reported a strong financial position with $4.5 billion in cash and marketable securities as of December 31, 2025.
Understanding Momentum Shifts in (ROIV)
This article analyzes momentum shifts for Roivant Sciences Ltd. (ROIV), highlighting weak near and mid-term sentiment but a strong long-term outlook. It presents AI-generated trading strategies for different risk profiles, including long, breakout, and short positions, and details multi-timeframe signal analysis with support and resistance levels. The report emphasizes an exceptional risk-reward setup targeting a 12.6% gain.
Short Interest in Roivant Sciences Ltd. (NASDAQ:ROIV) Increases By 25.3%
Short interest in Roivant Sciences Ltd. (NASDAQ:ROIV) significantly increased by 25.3% to 24,529,353 shares as of January 15th, representing 4.0% of the stock. This rise in short interest comes amidst notable insider selling, with major shareholders Vivek Ramaswamy and Daniel Allen Gold selling a combined total of over a million shares in December. Despite the increased short interest and insider sales, analysts generally maintain a "Moderate Buy" rating with several firms raising their price targets for ROIV.
Roivant Sciences Ltd. (NASDAQ:ROIV) Given Consensus Recommendation of "Moderate Buy" by Analysts
Analysts have issued a consensus "Moderate Buy" recommendation for Roivant Sciences Ltd. (NASDAQ:ROIV) from ten firms, with an average 1-year price target of $25.19. Despite this positive outlook, company insiders have recently been net sellers, offloading shares worth approximately $266.4 million over the past 90 days. The stock is currently trading at $22.02 with a market capitalization of $15.31 billion and institutional ownership around 64.8%.
Avoiding Lag: Real-Time Signals in (ROIV) Movement
The article discusses the real-time signals for Roivant Sciences Ltd. (NASDAQ: ROIV), highlighting a weak near-term sentiment that could precede shifts in mid and long-term outlook. It identifies an exceptional 40.1:1 risk-reward short setup and outlines three AI-generated institutional trading strategies based on different risk profiles and holding periods, including position trading, momentum breakout, and risk hedging. The analysis also provides multi-timeframe signal strengths and support/resistance levels for the stock.
Y Intercept Hong Kong Ltd Buys 601,178 Shares of Roivant Sciences Ltd. $ROIV
Y Intercept Hong Kong Ltd significantly increased its holdings in Roivant Sciences Ltd. by 221.1% in the third quarter, acquiring 601,178 additional shares. This brings their total stake to 873,081 shares, valued at approximately $13.21 million. Despite substantial insider selling from Mayukh Sukhatme and CFO Richard Pulik, Roivant Sciences maintains a "Moderate Buy" consensus rating from analysts with an average price target of $25.19.
